Navigation Links
New Mixing Method for Microchip-Sized Labs

"Because up to 75 percent of breast cancer patients have an abnormality in a specific cell signaling pathway, drugs that target different molecules along that pathway may be especially effective for treating the disease, says a researcher from The University of Texas M. D. Anderson Cancer Center."

A clearer picture is now emerging about the importance of the phosphatidylinositol 3 kinase (PI3K) pathway to breast cancer development, says Gordon Mills, M.D., Ph.D., a professor and chair of the Department of Molecular Therapeutics. This pathway, which is linked to critical growth factor receptors and is involved in programmed cell death, is aberrant at multiple levels in breast cancer, including mutations in PI3K itself or its many “downstream?players, such as PTEN, or AKT. “There is a lot of crosstalk between the PI3K pathway and other pathways, a lot of feed-forward and feedback loops,?says Mills. “But I and others believe there are central nodes between these intersecting circles that can be effectively targeted with drugs.?Only one PI3K pathway inhibitor is in use to date, but others are increasingly being developed and tested, says Mills, who is discussing the importance of this pathway at the annual San Antonio Breast Cancer Symposium meeting. “At least 20 different companies have recognized the importance of the pathway in breast cancer and are trying to develop drugs that target it.?In the future, breast cancer tissue samples from newly diagnosed patients can be tested for their specific PI3K pathway abnormality in order to find a drug that zeroes in on what may be the cancer’s Achilles?heel, Mills says. “Using those drugs in combination with other treatments such as chemotherapy may significantly advance breast cancer care,?he says.
'"/>

Source:


Page: 1

Related biology news :

1. Computational Method Speeds Mapping of Cell Signaling Networks
2. Method slashes quantum dot costs by 80 percent
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/16/2017)... , May 16, 2017   Bridge ... health organizations, and MD EMR Systems , ... development partner for GE, have established a partnership ... Portal product and the GE Centricity™ products, including ... EMR. These new integrations will ...
(Date:4/18/2017)... 2017  Socionext Inc., a global expert in SoC-based imaging and ... the M820, which features the company,s hybrid codec technology. A demonstration ... Probe, Inc., will be showcased during the upcoming Medtec Japan at ... the Las Vegas Convention Center April 24-27. ... Click here for an ...
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... CA (PRWEB) , ... October 11, 2017 , ... ... upregulate any gene in its endogenous context, enabling overexpression experiments and avoiding the ... system with small RNA guides is transformative for performing systematic gain-of-function studies. ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , ... of Cancer Research, London (ICR) and ... with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple ... as MUK nine . The University of ... is partly funded by Myeloma UK, and ICR will perform ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive global ... technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, ...
(Date:10/10/2017)... ... 10, 2017 , ... USDM Life Sciences , the ... sciences and healthcare industries, announces a presentation by Subbu Viswanathan and Jennifer Jaye ... GxP Validation for Agile Cloud Platforms,” will present a revolutionary approach to achieving ...
Breaking Biology Technology: